Literature DB >> 19289613

Continuing trastuzumab beyond progression.

Mohammad Jahanzeb.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19289613     DOI： 10.1200/JCO.2008.20.8215

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies.

Authors:  Michael Luis; Ana Tavares; Liliana S Carvalho; Lúcio Lara-Santos; António Araújo; Ramon Andrade de Mello
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

2.  Lapatinib - Member of a New Generation of ErbB-Targeting Drugs.

Authors:  Michael Untch; Hans-Joachim Lück
Journal:  Breast Care (Basel)       Date:  2010-04-26       Impact factor: 2.860

3.  Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer.

Authors:  Yan-Xia Shi; Yu-Ting Tan; Zhong-Yu Yuan; Shu-Sen Wang; Rou-Jun Peng; Xin An; Ye Cao; Ying Jin; Xiu-Yu Cai; Yue-Li Sun; Xiao-Yu Teng; Dong-Geng Liu
Journal:  Med Oncol       Date:  2011-02-08       Impact factor: 3.064
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.